F. Hoffmann-La Roche Ltd: Roche to present new pivotal data at ASH 2021 from broad and comprehensive portfolio, challenging treatment standards for people with blood disorders

Phase III POLARIX trial showed Polivy plus R-CHP was the first treatment in two decades to significantly improve outcomes in newly diagnosed diffuse large B-cell lymphoma (DLBCL) versus the standard of

Related Keywords

United States ,American ,Nathalie Meetz ,Polatuzumab Vedotin ,Levi Garraway ,Mabthera Rituxan ,Gazyva Gazyvaro ,Sileia Urech ,Glofitamab Glofit ,Venclexta Venclyxto ,Karsten Kleine ,Rocheand Linkedinand ,Polatuzumab Vedotin Pola ,Venetoclax Rituximab Ven ,American Society Of Hematology ,Subcutaneous Sc Administration Of Mosunetuzumab ,Lymphoma Study Association ,Head Of Global Product Development ,Lymphoma Academic Research Organisation ,American Society ,Annual Meeting ,Chief Medical Officer ,Global Product ,Live Media Event ,Roche Haematology Newsroom ,Versus Rituximab ,Previously Untreated Diffuse Largeb Cell ,Well Tolerated Treatment Option ,Follicular Lymphoma ,Who Have Received ,Pivotal Results ,Plus Polatuzumab Vedotin Has Promising Efficacy ,Favorable Safety Profile ,Refractory Aggressiveb Cell Non Hodgkin Lymphoma ,Updated Results ,Lenalidomide Has ,Manageable Safety Profile ,Encouraging Activity ,Refractory Follicular Lymphoma ,Initial Results ,Refractoryb Cell Non Hodgkin Lymphomas ,Step Up Dosing Induces High Response Rates ,With Relapsed ,Mantle Cell Lymphoma ,Whom Had Failed Prior Bruton ,Tyrosine Kinase Inhibitor ,Data Support Manageable Safety ,Encouraging Efficacy ,Diffuse Largeb Cell Lymphoma ,Obinutuzumab Induces High Complete Response Rates ,Multiple Relapsed ,Hodgkin Lymphoma ,Non Hodgkin Lymphoma ,Previously Untreated ,Preliminary Results From ,Show Clinically Meaningful Activity ,Manageable Safety ,Heavily Pre Treated ,Refractory Multiple Myeloma ,Short Duration Infusion Is Preferred ,Healthcare Providers ,Has Minimal Impact ,Patient Reported Symptoms Among Patients ,Advanced Follicular ,Responses Are Observed ,Mutational Spectrum ,Venetoclax Plus ,Poor Risk Cytogenetics ,Venetoclax Combined ,Lymphocytic Leukemia ,Minimal Residual Disease ,Randomized Phase ,Moderate Hemophilia ,Interim Analysis ,Emicizumab Prophylaxis ,Thrombotic Events ,Patients With Paroxysmal Nocturnal Hemoglobinuria ,Current Anti Complement ,Trial Evaluating ,Acute Uncomplicated Vaso Occlusive Episodes ,Sickle Cell Disease ,Placebo Controlled Phase ,Crovalimab As Adjunct Treatment ,Vaso Occlusive Episodes ,World Health Organization Model Lists ,Essential Medicines ,Dow Jones Sustainability ,Hoffmann ,Oche ,Present ,Pivotal ,Data ,021 ,Rom ,Road ,Comprehensive ,Portfolio ,Challenging ,Treatment ,Standards ,People ,Flood ,Disorders ,